指南与共识治疗药物监测与药物基因组学药物不良反应与药物警戒肝肾功能剂量调整

大剂量甲氨蝶呤药物治疗:中国药理学会治疗药物监测分会的循证实践指南

Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society.
指南 / 共识 · Br J Clin Pharmacol · 2022-02-08

中国药理学会治疗药物监测分会遵循WHO指南制定手册和循证医学方法,通过系统评价和多中心横断面调查(124例患者)整合患者价值观与偏好,采用GRADE分级,最终形成28条推荐(12条强推荐),涵盖大剂量甲氨蝶呤用药前评估、给药方案、治疗药物监测、亚叶酸钙救援及毒性管理全过程。

要点

  • 用药前需评估肾功能、肝功能、胸腔积液、合并用药及基因检测。
  • 治疗药物监测需明确必要性、方法、时机及目标浓度。
  • 亚叶酸钙救援需规范初始时机、剂量方案及优化策略。

核心结论

  • 该指南基于严谨的多学科方法制定,为大剂量甲氨蝶呤用药全过程提供全面实用的推荐。

研究设计与样本

  • 由中国药理学会治疗药物监测分会发起,遵循WHO指南制定手册和循证医学方法,并在国际实践指南注册平台注册(IPGRP-2017CN021)。
  • 通过系统评价综合证据,并开展多中心横断面问卷调查(124例患者)整合患者价值观与偏好,采用GRADE分级评估证据质量和推荐强度。

主要发现

  • 指南工作组包括临床医生、药师、方法学家、药理学家和药物经济学专家等多学科成员。
  • 最终形成28条推荐,其中12条为强推荐。

关键数值与推荐

  • 推荐涉及用药前评估(肾功能、肝功能、胸腔积液、合并用药、基因检测)、治疗前及常规给药方案、治疗药物监测(必要性、方法、时机、目标浓度)、亚叶酸钙救援(初始时机、剂量方案及优化)和毒性管理。
  • 28条推荐中12条为强推荐。

临床怎么用

  • 临床药学智能体医生可参照本指南对大剂量甲氨蝶呤用药全过程进行规范化管理,包括用药前评估、给药、监测、救援及毒性处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: A lot of medication risks related to high-dose methotrexate (HDMTX) therapy still remain to be identified and standardized. This study aims to establish an evidence-based practice guideline for individualized medication of HDMTX. METHODS: The practice guideline was launched by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. The guideline was developed following the WHO handbook for guideline development and the methodology of evidence-based medicine (EBM). The guideline was initially registered in the International Practice Guidelines Registry Platform (IPGRP-2017CN021). Systematic reviews were conducted to synthesize available evidence. A multicentre cross-sectional study was conducted using questionnaires to evaluate patients' perception and willingness concerning individualized medication of HDMTX. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to rate the quality of evidence and to grade the strength of recommendations. RESULTS: Multidisciplinary working groups were included in this guideline, including clinicians, pharmacists, methodologists, pharmacologists and pharmacoeconomic specialists. A total of 124 patients were involved to integrate patient values and preferences. Finally, the guideline presents 28 recommendations, regarding evaluation prior to administration (renal function, liver function, pleural effusion, comedications, genetic testing), pre-treatment and routine dosing regimen, therapeutic drug monitoring (necessity, method, timing, target concentration), leucovorin rescue (initial timing, dosage regimen and optimization), and management of toxicities. Of these, 12 are strong recommendations. CONCLUSIONS: We developed an evidence-based practice guideline with respect to HDMTX medication using a rigorous and multidisciplinary approach. This guideline provides comprehensive and practical recommendations involving the whole process of HDMTX administration to health care providers.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Song Z, Hu Y, Liu S, et al. Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Br J Clin Pharmacol. 2022. PMID: 34729817. doi:10.1111/bcp.15134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。